The most deadly complication of Plasmodium falciparum infection is cerebral malaria (CM) with a case fatality rate of 15-25% in African children despite effective antimalarial chemotherapy. There are no adjunctive treatments for CM, so there is an urgent need to identify new targets for therapy. Here we show that the glutamine analog 6-diazo-5-oxo-L-norleucine (DON) rescues mice from CM when administered late in the infection a time at which mice already are suffering blood-brain barrier dysfunction, brain swelling, and hemorrhaging accompanied by accumulation of parasite-specific CD8 + effector T cells and infected red blood cells in the brain. Remarkably, within hours of DON treatment mice showed blood-brain barrier integrity, reduced brain swelling, decreased function of activated effector CD8 + T cells in the brain, and levels of brain metabolites that resembled those in uninfected mice. These results suggest DON as a strong candidate for an effective adjunctive therapy for CM in African children.
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cerebral malaria | adjunctive therapy | CD8 + T cells | glutamine metabolism | DON T he World Health Organization estimates that there are nearly 200 million clinical cases of Plasmodium falciparum malaria annually (1) . For most individuals living in endemic areas, malaria is uncomplicated and resolves with time. However, in about 1% of cases, almost exclusively among young children, malaria becomes severe and life threatening, resulting in 525,000 deaths each year in Africa alone. One of the most deadly complications of P. falciparum infection in humans is cerebral malaria (HCM) characterized by the onset of severe neurological signs such as altered consciousness, seizures, and coma (2) . Autopsy and MRI analyses of brains of children with HCM indicate sequestration of infected red blood cells (iRBCs), microhemorrhaging, breakdown of the blood-brain barrier (BBB) (3) , and a fatal increase in intracranial pressure resulting from edema (4, 5) . At present, despite effective antimalarial drug treatment, mortality for children presenting with HCM remains high, at 15-25%. HCM takes a second toll on African children, leaving survivors at risk for debilitating neurological defects (6) . Thus, there is an urgent need for the development of effective adjunctive therapies that can be used in conjunction with antimalarials to treat children with HCM.
Experimental cerebral malaria (ECM) in mice is a widely used model of HCM and provides a valuable tool for elucidating the mechanisms involved in CM pathogenesis and identifying cellular and molecular targets for adjunctive therapy (7) . In ECM, 6-7 d after infection with Plasmodium berghei ANKA (PbA), mice of susceptible strains, such as C57BL/6, develop ataxia, paralysis, seizures, and coma and ultimately die (8) . ECM displays key features of HCM, including BBB breakdown, focal hemorrhaging, and brain swelling (9) (10) (11) . ECM's pathology also requires sequestration of iRBCs in the brain vasculature (12) , a hallmark of HCM (3) . Histological analysis of the brains of children who died of HCM showed leukocytes, primarily monocytes with phagocytized hemozoin and platelets but also intravasculature leukocytes, including CD8 + T cells, sequestered in the brain vessels (13, 14) . In ECM monocytes and both CD4 + and CD8 + T cells have been shown to accumulate in the brain by both flow cytometry and by intravital imaging (15) . Current evidence indicates that CD8 + T cells are the major mediators of death in ECM (16) and that antigen-specific CD8 + T cells engage parasite antigens cross-presented on MHC class I molecules on brain endothelium, resulting in endothelial cell dysfunction by a perforin-dependent mechanism (17) .
A critical role for metabolic reprogramming in regulating immune responses is becoming increasingly appreciated. Upon activation, T cells undergo metabolic reprogramming to meet the increased energetic and biosynthetic demands of growth and effector T-cell functions (18) (19) (20) . Reprogramming involves a shift to aerobic glycolysis and increased glutaminolysis. Activated T cells import large quantities of Gln and increase their expression of glutaminase (21) (22) (23) . Because the pathology leading to death in CM is believed to be in part immune mediated, we hypothesized that blocking T-cell metabolism might effectively mitigate the pathology leading to death in HCM. To this end, in the present Significance Cerebral malaria (CM) is a deadly complication of Plasmodium falciparum infection in African children despite effective antimalarial treatment. Once signs of neurologic disease have commenced, there is no adjunctive treatment for CM, and overall mortality remains high. Thus, a treatment that arrests disease and promotes healing in the late stages is urgently needed. Here we report, in an animal model of CM, that the glutamine analog 6-diazo-5-oxo-L-norleucine (DON) is an effective therapy even when treatment is initiated after infected animals show neurological signs of disease. Within hours of DON treatment blood-brain barrier integrity was restored, and brain swelling was reduced. These results suggest DON as a strong candidate for an effective adjunctive therapy for CM in African children. study we focus on targeting Gln metabolism for an adjunctive therapy for CM using the Gln analog 6-diazo-5-oxo-L-norleucine (DON). DON broadly inhibits Gln metabolism, in part by blocking Gln transport and inhibiting all three isoforms of glutaminase as well as other Gln-using enzymes such as the amidotransferases and glutamine synthetase (24) . Consequently, DON has been shown to be a potent inhibitor of T-cell proliferation (22) .
Here we show that DON treatment rescues PbA-infected mice from ECM at late stages in the disease, at a time when the animals show clinical signs of neurological damage and physical loss of BBB integrity, brain swelling, and hemorrhaging. The ability of DON to arrest disease is concomitant with a decrease in the effector function of parasite-specific CD8 + T cells in the brains of treated mice. However, the striking ability of DON treatment to arrest pathology and promote survival so late in the disease suggests a fundamental and potentially direct role for Gln metabolism in promoting neuropathology. Overall, these results suggest DON as a candidate for an adjunctive therapy for HCM in African children.
Results
DON Treatment Promotes Survival Even in Late-Stage ECM. To determine if blocking Gln metabolism would inhibit death caused by immunopathology in a mouse model of ECM, C57BL/6 mice were infected with PbA on day 0 and were injected i.p. with DON (1.3 mg/kg) or saline, beginning at 7:00 AM on the morning of day 5 p.i. (day 5a p.i.), at 11:00 PM on day 5 p.i. (day 5p p.i.), or at 7:00 AM on day 6 p.i. (day 6a p.i.). DON treatments were repeated either every day or every other day (Fig. S1 ). The majority of untreated PbA-infected mice died during day 6 p.i., and all died by day 7 p.i. (Fig. 1A) . In contrast, all the mice treated with DON beginning on day 5a p.i. and 80% of the mice treated on day 5p p.i. survived as followed until day 12 p.i. Remarkably, nearly 50% of mice treated as late as day 6a p.i. survived.
Mice were evaluated for the development of neurological signs associated with ECM and were given clinical scores between 0 (no signs) to 10 (moribund) using previously described criteria (25) . Nearly all the untreated mice that were infected with PbA developed neurological signs by day 5p p.i. that in most cases were severe (clinical score >6) by day 6a p.i. (Fig. 1B) . Treatment with DON beginning on day 5a p.i. prevented the development of neurological symptoms in all PbA-infected mice ( Fig. 1B) . Treatment of mice with DON beginning on day 5p p.i., a point at which most mice had clinical scores of 2, not only prevented the worsening of clinical signs but promoted the rapid resolution of symptoms ( Fig. 1B ). Remarkably, treatment of mice on day 6a p.i., when many mice already had developed clinical scores of 5, blocked the progression of the disease and rapidly resolved the symptoms in half of the mice (Fig.  1B ). Thus, DON was able to arrest disease and promote healing even when the mice already were displaying signs of neurologic damage. A scatter plot showing the clinical scores of individual mice on the day of treatment and the resulting outcome of treatment is given in Fig. S2 . For mice treated with DON on d5p p.i., the clinical scores on the day of DON treatment (which ranged from 0 to 6) did not distinguish the mice that survived from those that died, even though the average clinical score was significantly higher for mice that died following treatment. For mice treated with DON on day 6a p.i., clinical scores below 8 did not distinguish the mice that survived from those that did not. However, all mice with clinical scores of 9 or 10 died following DON treatment, indicating that there is a tipping point clinically at which mice no longer can be rescued by DON treatment.
In both DON-treated and untreated PbA-infected mice parasitemia increased similarly with time, reaching peak levels of ∼8-12% between d5 and d6 p.i. (Fig. 1C ). Nearly all untreated mice died by day 7 p.i., with peripheral parasitemia of 10-12%. In the DONtreated mice that survived beyond day 6 p.i., the peripheral parasitemia decreased beginning on day 7 p.i., reaching low levels by day 8 p.i. However, during the critical period of day 6 p.i., during which untreated mice die and DON treated mice survive, the parasite loads were indistinguishable in the brains of treated and untreated mice ( Fig. 1D ), suggesting that inhibition of parasite growth by DON is not the primary mechanism promoting survival. Consistent with the ability of DON to inhibit parasite replication, continued DON treatment suppressed parasitemia to under 5% as followed out to day 17 p.i., and when DON treatment was stopped, parasitemia increased to a mean of 40% by day 21 p.i. (Fig. S3 ).
DON Treatment Promotes Recovery of BBB Integrity and Reduction in Brain Swelling but Does Not Have an Immediate Effect on Brain
Hemorrhaging. Compromise of the BBB, brain swelling, and hemorrhaging are major components of the neuropathology observed in ECM. Thus, we assessed the effect of DON treatment on the integrity of the BBB by measuring the leakage of the dye Evans blue (EB) into the brains (26, 27) . Mice were injected retroorbitally with EB and were killed 3 h later; then their brains removed, and EB was quantified. Both visual inspection ( Fig. 2A ) and EB quantification ( Fig. 2B ) showed significant leakage of EB into the brains of PbA-infected, untreated mice on day 5p p.i., and the leakage increased further on day 6a p.i. (Fig. 2 A and B) . Remarkably, on day 6a p.i. EB leakage was significantly less in the brains of PbA-infected DON-treated mice than in the brains of untreated mice, and the EB leakage in the brains of PbA-infected DON-treated mice decreased significantly further by day 7a p.i. (Fig. 2 A and B) .
We also determined the effect of DON treatment on the water content of the brain as a measure of cerebral edema by weighing the brains before and after desiccation. The brains of PbA-infected mice had significantly greater water content than the brains of uninfected mice on both day 5p p.i. and day 6a p.i. (Fig. 2C ). Treating mice with DON on day 5p p.i. significantly reduced the water content of the brains measured on day 6a p.i. Thus, DON not only arrested the disease process; it also promoted resolution even when treatment was initiated at a time when significant BBB dysfunction and brain swelling already were manifest.
To quantify brain hemorrhages, brain sections were stained with H&E. PbA-infected, untreated mice developed petechial hemorrhages throughout the brain by day 5p p.i. that increased in number by day 6a p.i. (Fig. 2 D and E) . Treatment of mice with DON beginning on day 5p p.i. had no significant effect on the number of hemorrhages that developed. However, by day 15 p.i. the hemorrhages were no longer evident ( Fig. 2 D and E) . Thus, DON-treated mice survived local hemorrhaging in the brain when the overall integrity of the BBB was restored and brain swelling was reduced. (16), and Gln metabolism is critical for the differentiation, proliferation, and function of effector T cells. Thus, we determined the effect of DON treatment on T cells in the brains of infected mice. DON was administered to PbA-infected mice on day 5p p.i., and on day 6a p.i. mice were terminally anesthetized and transcardially perfused with cold PBS. The brains were collected, and single-cell suspensions were prepared and analyzed by flow cytometry. First we examined immune cell infiltration of both the treated and untreated mice. Compared with uninfected mice, the brains of infected mice showed large increases in all immune cell types analyzed, including CD8 + and CD4 + T cells, neutrophils, macrophages, and natural killer (NK) cells. Interestingly, despite its ability to reverse disease, DON treatment had no effect on the numbers of immune cells in the brains of infected mice ( Fig. 3 A-E) .
Next, we examined the effect of DON on the expansion and function of parasite-specific CD8 + T cells. The accumulation of PbAspecific CD8 + T cells in the brains and spleens was quantified using a peptide-MHC class I tetramer composed of the PbA glideosomeassociated protein 50 (GAP50) peptide, SQLLNAKYL, bound to MHC class I D b (referred to as a GAP50-tetramer) that identifies ∼5% of splenic CD8 + T cells in PbA-infected mice (28) . We verified that in the spleens of uninfected mice the frequency of GAP50-tetramer-binding CD8 + T cells was less than 0.1% (Fig. 3F, Left) . Enrichment for GAP50-tetramer-binding cells in the spleen and lymph nodes of uninfected mice by GAP50-tetramer-bound magnetic bead purification showed ∼2,700 GAP50-tetramer-binding CD8 + T cells, the majority of which were resting CD44 − cells (Fig. 3F, Center) . In contrast, in PbA-infected mice the frequency of GAP50-tetramerbinding T cells in the spleen was ∼3%, and these were CD44 + effector T cells (Fig. 3F Right) . DON treatment of PbA-infected mice resulted in a small decrease in the number of GAP50-tetramer-binding CD8 + T cells in the spleens but had little effect on the number of GAP50tetramer-binding T cells in the brains (Fig. 3G) .
Having observed that DON did not inhibit expansion of parasitespecific CD8 + T cells, we determined the effect of DON on CD8 + T-cell effector function. The development of ECM has been shown to be dependent on degranulation and perforin release of CD8 + T cells that accumulate in the brains of PbA-infected mice (16) . Degranulation of CD8 + T cells results in the expression of CD107 on their plasma membranes. To assess the ability of DON to inhibit CD8 + T-cell degranulation in the brains of infected mice, fluorescently labeled CD107-specific mAbs were administered i.v. to mice 1 h before tissues were removed for analysis to allow in vivo labeling of CD107 + cells. Shown are representative flow cytometry plots showing the percent of CD44 + , CD8 + T cells that express CD107 in the spleens of uninfected mice, PbA-infected mice, and PbA-infected mice treated with DON ( Fig. 3H ). DON treatment of PbA-infected mice resulted in significant decreases in the percent of CD8 + T cells that were CD107 + in both the spleens and brains (Fig.  3I ). The percent of GAP50-tetramer-binding CD8 + T cells that were CD107 + also decreased significantly in the brains of PbA-infected mice (Fig. 3J) . Thus, although the late-stage treatment of DON does not block the expansion of the PbA-specific CD8 + T cells, it appears to block their effector function as measured by degranulation. (Table S1 ). Principal components were determined from all detectable metabolites for the brain (438 metabolites) (A), liver (544 metabolites) (B), and serum (563 metabolites) (C). Each sphere represents one tissue sample from one mouse. (D) Venn diagram showing the number of differentially abundant brain metabolites for the two main comparisons: infected, untreated mice vs. uninfected, untreated mice and infected, DON-treated mice with low clinical scores vs. infected, untreated mice. Differential abundance thresholds were an absolute fold-change in abundance of ≥1.2 and a false-discovery rate of <5% (Welch's t test) .
pathology, DON also might affect pathology induced by altered brain metabolism. To investigate this possibility, we profiled metabolites in the brain, liver, and serum from five groups of mice that differed in their infection, treatment, and/or clinical status (Table S1 ). Principal component analysis of all detected metabolites revealed distinct clustering of samples according to infection status in all tissues ( Fig. 4 A-C). Notably, we observed that infected, DON-treated mice with low clinical scores (<6) clustered with uninfected mice for metabolites in the brain (Fig. 4A) . In contrast, when we examine the effect of DON on systemic metabolism, as determined by serum metabolites, or the effect of DON on liver metabolism, this correlation did not hold ( Fig.  4 B and C) , suggesting that DON treatment in ECM results in specific effects on brain metabolites. Because DON blocks the initial step in cellular glutaminolysis by inhibiting glutaminase (24) (Fig. S5A) , we first examined the metabolites of glutaminolysis and observed that PbA infection alone affects these metabolites differently in the brain than in the liver and serum. However, we did not observe a clear pattern predicted for treatment with a glutaminase inhibitor (Fig. S5B ). Of the 144 brain metabolites that changed significantly in infected versus uninfected mice, 81 overlapped with the 89 significantly affected metabolites identified by comparing infected, DON-treated mice with low clinical scores and infected, untreated mice ( Fig. 4D ). Pathways significantly affected by PbA infection involved citrulline metabolism, the urea cycle, or nitric oxide biosynthesis (aspartate, citrulline, ornithine, and urea) and were similar to pathways affected by DON treatment of PbA-infected mice (Fig. S6 ). Strikingly, all 81 overlapping metabolites were metabolites that were reversed by DON treatment (Table S2 ). Unsupervised hierarchal clustering analysis on these 81 brain metabolites accurately grouped the samples by infection, treatment, and clinical status ( Fig. 5) , with 9 of 10 PbA-infected, DONtreated mice with low clinical scores (<6) clustering together and demonstrating remarkable metabolic similarities to uninfected mice. DON appears to reverse brain metabolism associated with disease or to prevent the metabolic perturbation, presumably acting through its immunomodulatory effects or acting directly on brain metabolism. Although these data do not identify the specific metabolites promoting disease, they do identify a set of metabolites which are specifically associated with ECM and are selectively blocked by treatment with DON.
Discussion
HCM is a deadly complication of P. falciparum malaria despite treatment with effective antimalarial drugs. That is, even in when the replication of P. falciparum is effectively suppressed, there is no effective adjunctive treatment for HCM once signs of neurologic disease have commenced, and overall mortality remains high. Therefore a treatment that can arrest disease and promote healing in the late stages is urgently needed. Here we report that the Gln analog DON is an effective therapy for ECM even when treatment is first initiated after infected animals show neurological signs of disease. This clinical response was accompanied by the ability of DON to inhibit pathology as measured by decreases in BBB dysfunction, brain swelling, and degranulation of parasite-specific CD8 + T cells that accumulated in the brain. Furthermore, DON is able to reverse or prevent metabolic changes associated with the disease state.
Previously, DON was shown to have antiparasitic activity, albeit weak, both in vitro and in vivo (29, 30) . Although the antiparasitic activity of DON may contribute to its ability to arrest ECM and promote healing, we do not believe plays a critical role. Indeed, DON had little effect on the parasite load in the brains of PbA-infected mice during the critical period when the BBB was restored and brain swelling decreased in DON-treated mice.
On the other hand, CD8 + effector T cells that release perforin have been shown to play a critical role in promoting the pathogenesis that constitutes ECM (16) . CD8 + T-cell activation results in a dramatic shift from oxidative metabolism to aerobic glycolysis and glutaminolysis necessary for T-cell expansion and effector function (18) (19) (20) . Both T-cell cytokine production and proliferation are blocked by restricting the availability of extracellular Gln (21) or by treating T cells with DON (22) . DON treatment of PbA-infected mice did not prevent or decrease the accumulation of CD8 + T cells in the brain. Rather, the number of CD8 + T cells that degranulated was decreased following DON treatment. These observations suggest that DON's protective effect is mediated not by preventing the proliferation and generation of CD8 + effector T cells but rather by blocking CD8 + T-cell effector function. The ability of DON to block CD8 + T-cell function may account, in part, for the remarkably fast kinetics by which DON mediates its protective effect. The ability of DON to promote survival at such a late stage of the disease when animals are suffering from BBB dysfunction and brain swelling distinguishes our findings from all other attempts to treat and reverse ECM.
Although our studies were motivated by the ability of DON to inhibit immune function, we also investigated the effect of DON . Recovery from ECM with DON treatment is associated with normal brain metabolites. Clustering heat map showing the normalized abundance of the 81 metabolites that were shared between the two main comparisons in Fig. 4D . Each row is a metabolite, and each column represents brain tissue from a single mouse. Unsupervised hierarchical clustering of samples was performed using Ward's method for linkage analysis and Pearson's dissimilarity as distance measure. Metabolites were grouped according to pathway annotations (labels at right). treatment on infected brain metabolism by interrogating the brain for known metabolites. To this end, we observed more than 81 metabolic changes in the brains of infected mice compared with uninfected mice that were either reversed or blocked by DON. Unequivocally, such findings do not reveal the mechanism by which DON mediates its effects. The complexity of the fluctuations in Gln and Glu levels in the brain during infection and upon treatment most likely reflects DON's inhibition not only of glutaminase activity but also of Gln transport and other Gln-using enzymes (24) . Rather, the changes we identified provide a metabolic profile, a biomarker for diseased brains in ECM. Notably, although these 81 metabolites correlated with DON treatment and disease state in the brain, such correlations were not observed in the serum or the livers of the DON-treated mice.
In summary, we demonstrate, for the first time to our knowledge, the ability of a pharmacologic intervention to arrest disease and promote survival in the late stages of ECM. Because of the high mortality in HCM once neurologic symptoms are manifested, our findings have relevant and immediate clinical implications. Furthermore, our studies reveal a potentially selective metabolic signature for ECM and the subsequent reversal of diseases. It will be of interest to determine if this signature is applicable to other neurologic disorders and whether DON might be capable of arresting and/or reversing a broad spectrum of neuroinflammatory diseases.
Materials and Methods
All experiments were approved by the National Institute of Allergy and Infectious Diseases Animal Care and Use Committee (NIAID ACUC). The NIAID ACUC approved the Animal Study Proposal identification number LIG-1E, which adheres to the regulations of the Animal Welfare Regulations and Public Health Service Policy on Humane Care and Use of Laboratory Animals.
Detailed materials and methods can be found in SI Materials and Methods. C57BL/6 mice were infected with PbA and monitored for peripheral blood parasitemia (31) and ECM clinical scores (25) . DON (1.3 mg/kg) was administered i.p. Parasite loads were quantified by quantitative PCR in brain tissue taken from mice that were anesthetized and transcardially perfused (32) . Terminal assays also were carried out to quantify brain pathology. BBB integrity was assessed by quantifying EB in brains of mice that were injected with EB intraorbitally 3 h before the mice were anesthetized and transcardially perfused and the brains were removed (33) . Brain swelling was measured by weighing brains before and after desiccation. Brain hemorrhages were quantified by histological examination of H&E-stained brain sections. To characterize leukocytes that accumulated in brains, single-cell suspensions were prepared of brains from anesthetized and transcardially perfused mice. Cells were analyzed by flow cytometry using appropriately labeled antibodies specific for cell-surface markers and a CD8 + T-cell-specific GAP50-tetramer (28) . Single-cell suspensions of spleens were analyzed similarly. To quantify degranulation of T cells in vivo, mice were given phycoerythrin (PE)-conjugated antibodies specific for CD107a and CD107b i.v. 1 h before mice were killed and brains and spleens were removed for analysis by flow cytometry (34) . Metabolic profiling of brain, liver, and serum was performed at Metabolon (35) .
